FAG
HBIO icon

Fortitude Advisory Group’s Harvard Bioscience HBIO Stock Holding History

Fortitude Advisory Group’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-50
Closed -$3K – 643
2022
Q1 		$3K Hold
50
– – ﹤0.01% 1266
2021
Q4 		$4K Buy
+50
New +$3.56K ﹤0.01% 1237

Other funds holding HBIO

HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
2C
272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fortitude Advisory Group's HBIO Position: Q2 2022 in Review

Fortitude Advisory Group sold out of Harvard Bioscience (HBIO) in Q2 2022, closing a stake of 50 shares — an estimated $3K sold.

Fortitude Advisory Group first reported a position in HBIO in Q4 2021 and held it in 2 quarters. The position peaked at $4K in Q4 2021. 90 funds tracked by Wall St. Rank hold HBIO as of Q2 2022.

  • Fortitude Advisory Group reported no remaining Harvard Bioscience position as of Q2 2022 after selling out during the quarter.
  • Fortitude Advisory Group sold 50 Harvard Bioscience shares in Q2 2022, an estimated $3K.
  • Fortitude Advisory Group first reported a position in Harvard Bioscience in Q4 2021 and held it in 2 quarters.
  • Fortitude Advisory Group's Harvard Bioscience position peaked at $4K in Q4 2021.
  • 90 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2022.

Based on Fortitude Advisory Group's 13F filing for Q2 2022, filed 16 Aug 2022.